Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
delta-9-tetrahydrocannabinol + cannabidiol (Ferraz Lynce)
- Development stage
- Unknown
- Lead developer
- Ferraz Lynce
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Satalliv is an oral cannabinoid-based medicinal product containing a combination of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Developed by Ferraz Lynce Especialidades Farmaceuticas, it is currently being evaluated in Phase II clinical trials for the treatment of chronic neuropathic pain in patients with multiple sclerosis. The drug acts primarily through the modulation of the endocannabinoid system, where THC serves as a partial agonist of the cannabinoid receptors CB1 and CB2, and CBD acts as a non-competitive antagonist of CB1/CB2 receptors and a modulator of various other signaling pathways. This combination aims to provide analgesic effects while mitigating the psychoactive side effects typically associated with THC alone.
- Brand names
- Satalliv
- Other names
- THC/CBD
02
Targets
CNR2 (Cannabinoid receptor type 2)
Beyond the preview
Go deeper on delta-9-tetrahydrocannabinol + cannabidiol (Ferraz Lynce).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on delta-9-tetrahydrocannabinol + cannabidiol (Ferraz Lynce).